EC Number | Application | Comment | Organism |
---|---|---|---|
4.1.1.28 | medicine | the presence of a natural occurring ddc inhibitor in a peripheral tissue, may have interesting implications for future pharmacological treatment of neurodegenerative diseases such as inhibition of peripheral ddc, as well as, therapeutic approaches of neoplasias that are characterized by elevated levels of Ddc expression | Mus musculus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
4.1.1.28 | annexin 5 | endogenous inhibitor, identified and purified from human placenta presented in the membrane function, shows 30.4% inhibition by incubation of the human placenta samples in the presence of 0.34 unit ddc from mouse kidney homogenate. The inhibitor exhibits an optimum activity at 50 mM NaCl, pH 6.5, is heat labile and is deactivated by boiling. After incubation of the placental homogenate with proteinase K, inhibitory activity is partially abolished, suggesting that a population of inhibitor molecules is embedded in the membrane. | Mus musculus | |
4.1.1.28 | carbidopa | non-competitive inhibitor | Mus musculus | |
4.1.1.28 | NSD-1015 | non-competitive inhibitor | Mus musculus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
4.1.1.28 | L-3,4-Dihydroxyphenylalanine | Mus musculus | - |
Dopamine + CO2 | - |
? | |
4.1.1.28 | L-5-hydroxytryptophan | Mus musculus | - |
serotonin + CO2 | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
4.1.1.28 | Mus musculus | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
4.1.1.28 | kidney | obtained from normal individuals just after sacrifice by carbon dioxide | Mus musculus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
4.1.1.28 | L-3,4-Dihydroxyphenylalanine | - |
Mus musculus | Dopamine + CO2 | - |
? | |
4.1.1.28 | L-5-hydroxytryptophan | - |
Mus musculus | serotonin + CO2 | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
4.1.1.28 | AADC | - |
Mus musculus |
4.1.1.28 | Aromatic L-amino acid decarboxylase | - |
Mus musculus |
4.1.1.28 | DDC | - |
Mus musculus |
4.1.1.28 | L-DOPA decarboxylase | - |
Mus musculus |
EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|---|
4.1.1.28 | 37 | - |
assay at | Mus musculus |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
4.1.1.28 | pyridoxal 5'-phosphate | - |
Mus musculus |
EC Number | Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|---|
4.1.1.28 | additional information | - |
additional information | Samples containing varying amounts of the purified molecule are incubated in the presence of 0.34 U Ddc from mouse kidney homogenate at room temperature for 15 min. This results in an inhibitor quantity-dependent increase of Ddc activity inhibition. The inhibitory activity reaches saturation, when 1.8 microg of purified inhibitor are added to the reaction. Samples containing 0.9 microg of the purified inhibitor are incubated in the presence of 0.34 U Ddc from mouse kidney homogenate for varying time periods at room temperature, prior to estimation of their inhibitory activity. The purified molecule causes a time-dependent inhibition of Ddc, while there is no inhibitory activity at 0 min. The inhibitory activity is seen to reach a maximum effect at 30 min, before declining. | Mus musculus | |
4.1.1.28 | 0.000036 | - |
annexin 5 | inhibitor purified from mouse kidney homogenate ddc, classical non-competitive inhibitor | Mus musculus |